{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:35:05Z","timestamp":1776872105185,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["2878\/13"],"award-info":[{"award-number":["2878\/13"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["2878\/13"],"award-info":[{"award-number":["2878\/13"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11523-019-00656-2","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T16:02:34Z","timestamp":1563552154000},"page":"441-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane"],"prefix":"10.1007","volume":"14","author":[{"given":"Annelieke E. C. A. B.","family":"Willemsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolien","family":"Tol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne A.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob","family":"Meek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coline","family":"van Moorsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla M. L.","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"issue":"3","key":"656_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/bju.12692","volume":"116","author":"ND Shore","year":"2015","unstructured":"Shore ND. Advances in the understanding of cancer immunotherapy. BJU Int. 2015;116(3):321\u20139. \n                    https:\/\/doi.org\/10.1111\/bju.12692\n                    \n                  .","journal-title":"BJU Int."},{"key":"656_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188\u201396. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.034\n                    \n                  .","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"656_CR3","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1517\/17425255.2015.1080687","volume":"11","author":"LA Teuwen","year":"2015","unstructured":"Teuwen LA, Van den Mooter T, Dirix L. Management of pulmonary toxicity associated with targeted anticancer therapies. Expert Opin Drug Metab Toxicol. 2015;11(11):1695\u2013707. \n                    https:\/\/doi.org\/10.1517\/17425255.2015.1080687\n                    \n                  .","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"656_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-3-030-02505-2_6","volume":"995","author":"A Jain","year":"2018","unstructured":"Jain A, Shannon VR, Sheshadri A. Immune-related adverse events: pneumonitis. Adv Exp Med Biol. 2018;995:131\u201349. \n                    https:\/\/doi.org\/10.1007\/978-3-030-02505-2_6\n                    \n                  .","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"656_CR5","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1002\/ijc.29887","volume":"138","author":"AE Willemsen","year":"2016","unstructured":"Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm. Int J Cancer. 2016;138(10):2312\u201321. \n                    https:\/\/doi.org\/10.1002\/ijc.29887\n                    \n                  .","journal-title":"Int J Cancer"},{"issue":"3","key":"656_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11523-013-0289-2","volume":"9","author":"BA Gartrell","year":"2014","unstructured":"Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, et al. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 2014;9(3):195\u2013204. \n                    https:\/\/doi.org\/10.1007\/s11523-013-0289-2\n                    \n                  .","journal-title":"Target Oncol."},{"issue":"11","key":"656_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/JTO.0b013e3181ba20b1","volume":"4","author":"DA White","year":"2009","unstructured":"White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol. 2009;4(11):1357\u201363. \n                    https:\/\/doi.org\/10.1097\/JTO.0b013e3181ba20b1\n                    \n                  .","journal-title":"J Thorac Oncol."},{"issue":"6","key":"656_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1009290\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"6","key":"656_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10147-012-0494-5","volume":"17","author":"Y Saito","year":"2012","unstructured":"Saito Y, Gemma A. Current status of DILD in molecular targeted therapies. Int J Clin Oncol. 2012;17(6):534\u201341. \n                    https:\/\/doi.org\/10.1007\/s10147-012-0494-5\n                    \n                  .","journal-title":"Int J Clin Oncol."},{"issue":"5","key":"656_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/00007890-200109150-00008","volume":"72","author":"E Morelon","year":"2001","unstructured":"Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001;72(5):787\u201390.","journal-title":"Transplantation"},{"issue":"8","key":"656_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/01.TP.0000118413.92211.B6","volume":"77","author":"PT Pham","year":"2004","unstructured":"Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, et al. Sirolimus-associated pulmonary toxicity. Transplantation. 2004;77(8):1215\u201320.","journal-title":"Transplantation"},{"issue":"4","key":"656_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","volume":"29","author":"T Weichhart","year":"2008","unstructured":"Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008;29(4):565\u201377. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2008.08.012\n                    \n                  .","journal-title":"Immunity"},{"issue":"5","key":"656_CR13","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.transproceed.2013.02.110","volume":"45","author":"A Kezic","year":"2013","unstructured":"Kezic A, Becker JU, Thaiss F. The effect of mTOR-inhibition on NF-kappaB activity in kidney ischemia-reperfusion injury in mice. Transplant Proc. 2013;45(5):1708\u201314. \n                    https:\/\/doi.org\/10.1016\/j.transproceed.2013.02.110\n                    \n                  .","journal-title":"Transplant Proc."},{"issue":"5","key":"656_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11523-018-0596-8","volume":"13","author":"A Willemsen","year":"2018","unstructured":"Willemsen A, de Geus-Oei LF, de Boer M, Tol J, Kamm Y, de Jong PC, et al. Everolimus exposure and early metabolic response as predictors of treatment outcomes in breast cancer patients treated with everolimus and exemestane. Target Oncol. 2018;13(5):641\u20138. \n                    https:\/\/doi.org\/10.1007\/s11523-018-0596-8\n                    \n                  .","journal-title":"Target Oncol."},{"issue":"1","key":"656_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2012.09.019","volume":"81","author":"AJ van den Eertwegh","year":"2013","unstructured":"van den Eertwegh AJ, Karakiewicz P, Bavbek S, Rha SY, Bracarda S, Bahl A, et al. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. Urology. 2013;81(1):143\u20139. \n                    https:\/\/doi.org\/10.1016\/j.urology.2012.09.019\n                    \n                  .","journal-title":"Urology."},{"issue":"6","key":"656_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1109653\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"18","key":"656_CR17","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256\u201365. \n                    https:\/\/doi.org\/10.1002\/cncr.25219\n                    \n                  .","journal-title":"Cancer"},{"key":"656_CR18","doi-asserted-by":"crossref","unstructured":"Ito Y, Noguchi S, Deleu I, Baselga J, Hortobagyi GN, Bachelot TD et al. Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. J Clin Oncol. 2013;31(15):suppl; abstr 561.","DOI":"10.1200\/jco.2013.31.15_suppl.561"},{"issue":"3","key":"656_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11523-014-0310-4","volume":"9","author":"AE Willemsen","year":"2014","unstructured":"Willemsen AE, De Vos FY, Jansen A, de Boer M, Tjan-Heijnen VC, van Herpen CM. Diagnostic challenges of respiratory adverse events during everolimus treatment. Target Oncol. 2014;9(3):287\u201391. \n                    https:\/\/doi.org\/10.1007\/s11523-014-0310-4\n                    \n                  .","journal-title":"Target Oncol."},{"issue":"12","key":"656_CR20","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","volume":"42","author":"I Duran","year":"2006","unstructured":"Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006;42(12):1875\u201380. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2006.03.015\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"10","key":"656_CR21","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-13-2347","volume":"34","author":"K Park","year":"2014","unstructured":"Park K, Kim HJ, Lee JL, Lee KH, Jeong IG, Song C, et al. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus. Anticancer Res. 2014;34(10):5723\u20138.","journal-title":"Anticancer Res"},{"key":"656_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-physiol-012110-142250","volume":"73","author":"CG Lee","year":"2011","unstructured":"Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, et al. Role of chitin and chitinase\/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479\u2013501. \n                    https:\/\/doi.org\/10.1146\/annurev-physiol-012110-142250\n                    \n                  .","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"656_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.trsl.2012.01.012","volume":"159","author":"R Vij","year":"2012","unstructured":"Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res. 2012;159(4):218\u201327. \n                    https:\/\/doi.org\/10.1016\/j.trsl.2012.01.012\n                    \n                  .","journal-title":"Transl Res."},{"issue":"5","key":"656_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3899\/jrheum.100591","volume":"38","author":"M Hasegawa","year":"2011","unstructured":"Hasegawa M, Fujimoto M, Hamaguchi Y, Matsushita T, Inoue K, Sato S, et al. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. J Rheumatol. 2011;38(5):877\u201384. \n                    https:\/\/doi.org\/10.3899\/jrheum.100591\n                    \n                  .","journal-title":"J Rheumatol"},{"issue":"2","key":"656_CR25","first-page":"138","volume":"27","author":"A Kruit","year":"2010","unstructured":"Kruit A, Gerritsen WB, Pot N, Grutters JC, van den Bosch JM, Ruven HJ. CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):138\u201346.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"issue":"5","key":"656_CR26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jjco\/hys033","volume":"42","author":"R Mizuno","year":"2012","unstructured":"Mizuno R, Asano K, Mikami S, Nagata H, Kaneko G, Oya M. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42(5):442\u20136. \n                    https:\/\/doi.org\/10.1093\/jjco\/hys033\n                    \n                  .","journal-title":"Jpn J Clin Oncol"},{"key":"656_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1465-9921-12-32","volume":"12","author":"T Kondo","year":"2011","unstructured":"Kondo T, Hattori N, Ishikawa N, Murai H, Haruta Y, Hirohashi N, et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome. Respir Res. 2011;12:32. \n                    https:\/\/doi.org\/10.1186\/1465-9921-12-32\n                    \n                  .","journal-title":"Respir Res"},{"key":"656_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2017.04.029","volume":"121","author":"M Deppenweiler","year":"2017","unstructured":"Deppenweiler M, Falkowski S, Saint-Marcoux F, Monchaud C, Picard N, Laroche ML, et al. Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol Res. 2017;121:138\u201344. \n                    https:\/\/doi.org\/10.1016\/j.phrs.2017.04.029\n                    \n                  .","journal-title":"Pharmacol Res"},{"issue":"11","key":"656_CR29","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.3324\/haematol.11856","volume":"92","author":"T Buchler","year":"2007","unstructured":"Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin\u2019s disease\u2013a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica. 2007;92(11):e120\u20131. \n                    https:\/\/doi.org\/10.3324\/haematol.11856\n                    \n                  .","journal-title":"Haematologica"},{"issue":"6","key":"656_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000101517","volume":"30","author":"L von Rohr","year":"2007","unstructured":"von Rohr L, Klaeser B, Joerger M, Kluckert T, Cerny T, Gillessen S. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie. 2007;30(6):320\u20133. \n                    https:\/\/doi.org\/10.1159\/000101517\n                    \n                  .","journal-title":"Onkologie."},{"issue":"5","key":"656_CR31","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1080\/10428194.2016.1236379","volume":"58","author":"O Falay","year":"2017","unstructured":"Falay O, Ozturk E, Bolukbasi Y, Gumus T, Ornek S, Ozbalak M, et al. Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma. Leuk Lymphoma. 2017;58(5):1114\u201322. \n                    https:\/\/doi.org\/10.1080\/10428194.2016.1236379\n                    \n                  .","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"656_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/10428190902919200","volume":"50","author":"D Kalkanis","year":"2009","unstructured":"Kalkanis D, Stefanovic A, Paes F, Escalon MP, Serafini A, Lossos IS. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma. 2009;50(6):904\u201311. \n                    https:\/\/doi.org\/10.1080\/10428190902919200\n                    \n                  .","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"656_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/RLU.0b013e3181e4da5c","volume":"35","author":"BI Song","year":"2010","unstructured":"Song BI, Lee SW, Lee HJ, Kang S, Jeong SY, Seo JH, et al. Rituximab-induced pneumonitis on F-18 FDG PET\/CT in patient with non-Hodgkin lymphoma. Clin Nucl Med. 2010;35(8):601\u20133. \n                    https:\/\/doi.org\/10.1097\/RLU.0b013e3181e4da5c\n                    \n                  .","journal-title":"Clin Nucl Med"},{"issue":"4","key":"656_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12149-007-0109-9","volume":"22","author":"M Morikawa","year":"2008","unstructured":"Morikawa M, Demura Y, Mizuno S, Ameshima S, Ishizaki T, Okazawa H. FDG positron emission tomography imaging of drug-induced pneumonitis. Ann Nucl Med. 2008;22(4):335\u20138. \n                    https:\/\/doi.org\/10.1007\/s12149-007-0109-9\n                    \n                  .","journal-title":"Ann Nucl Med"},{"issue":"9","key":"656_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/RLU.0b013e318123f78d","volume":"32","author":"MC Post","year":"2007","unstructured":"Post MC, Grutters JC, Verzijlbergen JF, Biesma DH. PET scintigraphy of etoposide-induced pulmonary toxicity. Clin Nucl Med. 2007;32(9):683\u20134. \n                    https:\/\/doi.org\/10.1097\/RLU.0b013e318123f78d\n                    \n                  .","journal-title":"Clin Nucl Med"},{"issue":"8","key":"656_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s12149-008-0183-7","volume":"22","author":"T Yamane","year":"2008","unstructured":"Yamane T, Daimaru O, Ito S, Nagata T, Yoshiya K, Fukaya N, et al. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin\u2019s lymphoma. Ann Nucl Med. 2008;22(8):719\u201322. \n                    https:\/\/doi.org\/10.1007\/s12149-008-0183-7\n                    \n                  .","journal-title":"Ann Nucl Med"},{"issue":"6 Pt 1","key":"656_CR37","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1164\/ajrccm.152.6.8520796","volume":"152","author":"American Thoracic Society","year":"1995","unstructured":"American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique\u20141995 update. Am J Respir Crit Care Med. 1995;152(6 Pt 1):2185\u201398. \n                    https:\/\/doi.org\/10.1164\/ajrccm.152.6.8520796\n                    \n                  .","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"656_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"9","key":"656_CR39","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/1744666X.2016.1182426","volume":"12","author":"Y Miyazaki","year":"2016","unstructured":"Miyazaki Y, Tsutsui T, Inase N. Treatment and monitoring of hypersensitivity pneumonitis. Expert Rev Clin Immunol. 2016;12(9):953\u201362. \n                    https:\/\/doi.org\/10.1080\/1744666X.2016.1182426\n                    \n                  .","journal-title":"Expert Rev Clin Immunol."},{"issue":"3","key":"656_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1183\/09031936.02.00081102","volume":"19","author":"KE Greene","year":"2002","unstructured":"Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19(3):439\u201346.","journal-title":"Eur Respir J"},{"issue":"2","key":"656_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/rr19","volume":"1","author":"EC Crouch","year":"2000","unstructured":"Crouch EC. Surfactant protein-D and pulmonary host defense. Respir Res. 2000;1(2):93\u2013108. \n                    https:\/\/doi.org\/10.1186\/rr19\n                    \n                  .","journal-title":"Respir Res"},{"key":"656_CR42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01924-2015","author":"X Long","year":"2017","unstructured":"Long X, He X, Ohshimo S, Griese M, Sarria R, Guzman J, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur Respir J. 2017. \n                    https:\/\/doi.org\/10.1183\/13993003.01924-2015\n                    \n                  .","journal-title":"Eur Respir J"},{"issue":"8","key":"656_CR43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/bjc.2011.347","volume":"105","author":"R Shao","year":"2011","unstructured":"Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011;105(8):1203\u20139. \n                    https:\/\/doi.org\/10.1038\/bjc.2011.347\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"656_CR44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835de8ee","volume":"25","author":"K Bouabdallah","year":"2013","unstructured":"Bouabdallah K, Ribrag V, Terriou L, Soria JC, Delarue R. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr Opin Oncol. 2013;25(Suppl 2):S1\u201312. \n                    https:\/\/doi.org\/10.1097\/CCO.0b013e32835de8ee\n                    \n                  .","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"656_CR45","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909\u201318. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.08.185\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"9762","key":"656_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","volume":"377","author":"CJ van de Velde","year":"2011","unstructured":"van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321\u201331. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)62312-4\n                    \n                  .","journal-title":"Lancet"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00656-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-019-00656-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00656-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T23:26:50Z","timestamp":1595028410000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-019-00656-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1007\/s11523-019-00656-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"19 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was partly funded by Novartis (2878\/13).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nielka P. van Erp and Carla M.L. van Herpen have received an Investigator Driven Research Grant from Novartis from which part of the study presented was paid. Annelieke E. C. A. B. Willemsen, Jolien Tol, Marianne A. Jonker, Maaike de Boer, Bob Meek, Paul C. de Jong, Coline van Moorsel, Winald R. Gerritsen, and Jan C. Grutters declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}